Stifel upgraded Edwards Lifesciences (EW) to Buy from Hold with a price target of $90, up from $75. The firm said the upgrade is predicated on “now more credible TAVR growth re-acceleration potential.”
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EW: